Lai Kai Pharmaceutical-B (02105): LAE102 completed the first patient administration in the Phase I multi-dose expansion study for the treatment of obesity

According to the Zhitong Finance App, Lai Kai Pharmaceutical-B (02105) announced that the Group has initiated the enrollment of participants in the LAE102 Phase I multi-dose expansion study for the treatment of obesity in China, and has completed the administration of the first test subject.

The Phase I multi-dose extension study was a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of LAE102 (subcutaneous injection) in 60 overweight/obese subjects. The subjects will be randomly assigned to the LAE102 group or placebo group and treated for 6 months. Based on the positive one-month treatment results observed in previous MAD studies, this pre-planned multi-dose extension study aims to further evaluate the efficacy and safety characteristics after a longer period of continuous treatment. The Group is committed to providing this precise treatment for patients with obesity or metabolic diseases who require novel treatment options.